Assessing the Completeness of Reporting in Preclinical …
· Finally, a number of articles (n = 29, 12%) were published in Oncotarget, a journal that was recently delisted in MEDLINE.36 However, when comparing the level of reporting in Oncotarget to all other articles, we found no meaningful differences ().
位置: 8600 Rockville Pike, Bethesda, MD
What Value Do Journal Whitelists and Blacklists Have in …
· A recent example is that of Oncotarget, 65 an OA journal published by Impact Journals, that was delisted from the Web of Science and PubMed’s Medline, 66 with impassioned claims by the Editor-in-Chief, Mikhail V. Blagosklonny, that he and his journal were).
Download Impact Factor Of Oncotarget
· PDF 檔案Oncotarget Impact Factor, IF, number of article, detailed information and journal factor. ISSN: 1949-2553. Oncotarget Impact Factor IF 2019|2018|2017 – BioxBio The impact factor (IF) 2018 of Oncotarget is 3.71, which is computed in 2019 as per it’s
The Wonderful Adventures of Nils Billestrup with …
· Oncotarget (2015) doi: 10.18632/oncotarget.3158 The 2nd allegation was dismissed because the authors openly wrote in the text of the paper to have duplicated an image. “Allegation 2. The same image of cells is used in two different panels of Figure 1.
Mikhail V. Blagosklonny’s research works
A recent example is that of Oncotarget, 65 an OA journal published by Impact Journals, that was delisted from the Web of Science and PubMed’s Medline, 66 with impassioned claims by the Editor-in
Bridging to liver transplantation patients with a …
Oncotarget 2017;8:91328-42. [ Crossref ] [ PubMed ] Choi J, Shim JH, Shin YM, et al. Clinical significance of the best response during repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma.
Table 1 from The prevention of chemotherapy induced …
DOI: 10.18632/oncotarget.23467 Corpus ID: 3564776 The prevention of chemotherapy induced peripheral neuropathy by concurrent treatment with drugs used for bipolar disease: a retrospective chart analysis in human cancer patients
The Most Relied Upon Journals in Precision Oncology – …
Q: The medical world is running amuck with new information, some credible, some not. What are the most reliable sources of information in Precision Oncology? A: “Half of knowledge is knowing where to find knowledge”. No one knows how many medical journals
LetPub – Scientific Journal Selector
LetPub Scientific Journal Selector (2018-2021), RSC Advances published in 2011, England. Self-Citation Ratio (2019-2020) 5.10% Official Website http://pubs.rsc.org/en
[PDF] The prevention of chemotherapy induced …
Peripheral neuropathy is a major adverse effect in the use of chemotherapeutic drugs. In nearly 50% of patients, chemotherapy induced peripheral neuropathy (CIPN) has been reported as irreversible. With increasing numbers of patients surviving treatment as well as increasing duration of survival after treatment, reducing the side effects of chemotherapy and improving the quality of life has
Frontiers
Publishing decision solely based on journal impact factor rankings may have devastating consequences if a journal suddenly gets delisted by the Institute of Scientific Information: Exemplified by the once thriving journal Oncotarget, which was excluded in January
SEC Filing
Case Western reported data from a trial of intravenous TRC102 given in combination with Fludara in a Phase 1 clinical trial that were published in Oncotarget in 2017. Anti-tumor activity, including partial response, was noted in patients with lymphoma and chronic lymphocytic leukemia, including patients treated previously with Fludara.
Impact Factor Of Oncotarget 2017 2016 2015 2014
· PDF 檔案Oncotarget Impact Factor, IF, number of article, detailed information and journal factor. ISSN: 1949-2553. Oncotarget Impact Factor IF 2020 2019 2018 – BioxBio Of note, the Oncotarget issues from late 2018 and 2019 contained significantly fewer research papers
Janssen: New Amivantamab Data from CHRYSALIS Study …
Oncotarget 2016. 7 (48): 78985 – 78993 28 Lin JJ, Cardarella S, Lydon CA, Dahlberg SE, Jackman DM, Jänne PA, et al. Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with
Assessing the Completeness of Reporting in Preclinical …
Third, authors from countries outside of the United States and those who do not receive funding from the NIH may be unaware of these guidelines. Finally, a number of articles (n = 29, 12%) were published in Oncotarget, a journal that was recently delisted in
CUSP9* treatment protocol for recurrent …
· CUSP9 treatment protocol for recurrent glioblastoma was published one year ago. We now present a slight modification, designated CUSP9*. CUSP9* drugs- aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, sertraline, ritonavir, are all
Sirolimus‐based immunosuppression for liver …
Tumor Protocol patients waited a median of 56 days for transplant (mean 86 ± 109 days). One patient with a tumor > 5 cm in diameter was found to have a grade III tumor on biopsy and was delisted. Three patients were removed from the transplant list due to